

Oncology Today with Dr Neil Love: PARP Inhibition in the Management of Pancreatic Cancer (Interview Audio)**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. The POLO trial, investigating maintenance therapy with olaparib versus placebo for patients with metastatic pancreatic cancer who had a germline BRCA mutation, demonstrated which of the following outcomes with olaparib?**
 - a. A significant improvement in progression-free survival**
 - No significant improvement in progression-free survival
- 2. Which of the following statements is true regarding ATM mutations in patients with pancreatic cancer?**
 - They occur in about 1% of patients and confer lack of sensitivity to platinum chemotherapy
 - b. They occur in about 6% of patients and are associated with sensitivity to platinum chemotherapy**
- 3. Which of the following toxicities are class effects associated with PARP inhibitor therapy?**
 - Ocular and dermatologic toxicities
 - Neurologic and cardiovascular toxicities
 - c. Gastrointestinal toxicities and cytopenias**
- 4. In a study by Shroff and colleagues evaluating rucaparib as monotherapy for pancreatic cancer with BRCA1/2 mutations, a majority of the patients who responded to rucaparib had which of the following characteristics?**
 - a. Platinum-sensitive or platinum-naïve disease**
 - Platinum-refractory disease